ReferenceRRK6459

AC Immune

A Phase II Double-Blind Randomized Placebo-Controlled Adaptive Design Study to Assess the Safety Tolerability Immunogenicity and Target Engagement of ACI-24 Formulations in Patients with Mild Alzheimer’s Disease

Research Summary

Research Overview
Project Status Open
Study Run through CRF? No
Target number of patients agreed to recruit 6
Recruitment so far 0